These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3117533)

  • 1. Netilmicin disk susceptibility tests: effect of cations on the MIC correlates.
    Barry AL; Miller GH; Hare RS; Thornsberry C; Jones RN
    Eur J Clin Microbiol; 1987 Aug; 6(4):416-7. PubMed ID: 3117533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cation supplements on activity of netilmicin against Pseudomonas aeruginosa in vitro and in vivo.
    Barry AL; Miller GH; Thornsberry C; Hare RS; Jones RN; Lorber RR; Ferraresi R; Cramer C
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1514-8. PubMed ID: 3124731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa.
    Barry AL; Miller GH; Hare RS; Jones RN; Thornsberry C
    J Clin Microbiol; 1984 Mar; 19(3):311-4. PubMed ID: 6425354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tentative interpretive criteria for the diffusion susceptibility test using 30-microgram netilmicin disks.
    Jones RN; Barry AL; Thornsberry C
    Antimicrob Agents Chemother; 1980 Sep; 18(3):487-90. PubMed ID: 7425615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Netilmicin sulfate as single-agent therapy for Pseudomonas infections.
    Greenberg RN; Hansbrough JN; Lorber RR; Miller GH
    South Med J; 1989 Jun; 82(6):715-8. PubMed ID: 2499934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides.
    Barry AL; Reller LB; Miller GH; Washington JA; Schoenknect FD; Peterson LR; Hare RS; Knapp C
    J Clin Microbiol; 1992 Mar; 30(3):585-9. PubMed ID: 1551973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of 327 clinical isolates to netilmicin.
    Digranes A; Ostervold B; Madsen ST; Solberg CO; Haeger K
    J Int Med Res; 1978; 6(5):409-13. PubMed ID: 100353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of medium composition on bacterial susceptibility testing to gentamicin and netilmicin.
    Dornbusch K
    Scand J Infect Dis Suppl; 1980; Suppl 23():46-53. PubMed ID: 6937968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibilities of mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients against azthreonam, netilmicin and piperacillin.
    Flournoy DJ; Cox FR
    Methods Find Exp Clin Pharmacol; 1984 Sep; 6(9):487-9. PubMed ID: 6439964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa resistant to aminoglycosides: an assessment of the currently used methods of disk diffusion and dilution susceptibility.
    Ismaeel NA
    Microbios; 1991; 66(268-269):197-204. PubMed ID: 1907714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-h Identification of Pseudomonas aeruginosa with 9-chloro-9-(4-diethylaminophenyl)-10-phenylacridan.
    Davis JR; Stager CE; Araj GF
    J Clin Microbiol; 1983 Jun; 17(6):1054-6. PubMed ID: 6409921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of postantibiotic effects of imipenem and netilmicin alone and in combination against Pseudomonas aeruginosa.
    Hostacká A
    Arzneimittelforschung; 1997 Aug; 47(8):965-7. PubMed ID: 9296285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro activity of netilmicin against 357 clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.
    Digranes A; Dibb WL; Ostervold B
    Scand J Infect Dis Suppl; 1980; Suppl 23():30-3. PubMed ID: 6782655
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
    Majtán V; Hostacká A
    Folia Microbiol (Praha); 1996; 41(3):228-32. PubMed ID: 9449771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-micrograms disks.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1987 May; 7(1):77-82. PubMed ID: 3691036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin.
    Barry A; Fuchs P; Tenover F; Allen S; Hardy D; Jorgensen J; McLaughlin J; Reller L
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):822-6. PubMed ID: 7889952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical laboratory approach to evaluate administration dose of arbekacin. Reevaluation of in vitro MIC break points in the disk susceptibility test].
    Matsuo K; Uete T
    Jpn J Antibiot; 1994 Aug; 47(8):1041-52. PubMed ID: 7933533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity testing of Pseudomonas aeruginosa against netilmicin and gentamicin: aminoglycosides revisited.
    Taylor ME; Brogan TD
    J Infect; 1991 Mar; 22(2):209-11. PubMed ID: 1902863
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical laboratory approach for estimating effective administrative dose of cefsulodin].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 Sep; 37(9):1652-60. PubMed ID: 6439909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.